An Audible Demonstration Of The Speed Of Sound In Bubbly Liquids

The speed of sound in a bubbly liquid is strongly dependent upon the volume fraction of the gas phase, the bubble size distribution, and the frequency of the acoustic excitation. At sufficiently low frequencies, the speed of sound depends primarily on the gas volume fraction. This effect can be audibly demonstrated using a one-dimensional acoustic waveguide, in which the flow rate of air bubbles injected into a water-filled tube is varied by the user. The normal modes of the waveguide are excited by the sound of the bubbles being injected into the tube. As the flow rate is varied, the speed of sound varies as well, and hence, the resonance frequencies shift. This can be clearly heard through the use of an amplified hydrophone and the user can create aesthetically pleasing and even musical sounds. In addition, the apparatus can be used to verify a simple mathematical model known as Wood's equation that relates the speed of sound of a bubbly liquid to its void fraction. (c) 2008 American Association of Physics Teachers.Mechanical Engineerin

A terahertz grid frequency doubler

We present a 144-element terahertz quasi-optical grid frequency doubler. The grid is a planar structure with bow-tie antennas as a unit cell, each loaded with a planar Schottky diode. The maximum output power measured for this grid is 24 mW at 1 THz for 3.1-μs 500-GHz input pulses with a peak input power of 47 W. An efficiency of 0.17% for an input power of 6.3 W and output power of 10.8 mW is measured. To date, this is the largest recorded output power for a multiplier at terahertz frequencies. Input and output tuning curves are presented and an output pattern is measured and compared to theory

Cassiopeia A: dust factory revealed via submillimetre polarimetry

If Type-II supernovae - the evolutionary end points of short-lived, massive stars - produce a significant quantity of dust (>0.1 M_sun) then they can explain the rest-frame far-infrared emission seen in galaxies and quasars in the first Gyr of the Universe. Submillimetre observations of the Galactic supernova remnant, Cas A, provided the first observational evidence for the formation of significant quantities of dust in Type-II supernovae. In this paper we present new data which show that the submm emission from Cas A is polarised at a level significantly higher than that of its synchrotron emission. The orientation is consistent with that of the magnetic field in Cas A, implying that the polarised submm emission is associated with the remnant. No known mechanism would vary the synchrotron polarisation in this way and so we attribute the excess polarised submm flux to cold dust within the remnant, providing fresh evidence that cosmic dust can form rapidly. This is supported by the presence of both polarised and unpolarised dust emission in the north of the remnant, where there is no contamination from foreground molecular clouds. The inferred dust polarisation fraction is unprecedented (f_pol ~ 30%) which, coupled with the brief timescale available for grain alignment (<300 yr), suggests that supernova dust differs from that seen in other Galactic sources (where f_pol=2-7%), or that a highly efficient grain alignment process must operate in the environment of a supernova remnant.Comment: In press at MNRAS, 10 pages, print in colou

Investigating the prevalence and causes of prescribing errors in general practice : the PRACtICe Study

Report prepared by the University of Nottingham, University of Reading and University of Hertfordshir

The effectiveness of three types of practice in word recognition in grades II and III

Thesis (Ed.M.)--Boston Universit

Targeting danger molecules in tendinopathy: the HMGB1/TLR4 axis

Objectives: To seek evidence of the danger molecule, high-mobility group protein B1 (HMGB1) expression in human tendinopathy and thereafter, to explore mechanisms where HMGB1 may regulate inflammatory mediators and matrix regulation in human tendinopathy. Methods: Torn supraspinatus tendon (established pathology) and matched intact subscapularis tendon (representing ‘early pathology’) biopsies were collected from patients undergoing arthroscopic shoulder surgery. Control samples of subscapularis tendon were collected from patients undergoing arthroscopic stabilisation surgery. Markers of inflammation and HMGB1 were quantified by reverse transcriptase PCR (RT-PCR) and immunohistochemistry. Human tendon-derived primary cells were derived from hamstring tendon tissue obtained during hamstring tendon anterior cruciate ligament reconstruction and used through passage 3. In vitro effects of recombinant HMGB1 on tenocyte matrix and inflammatory potential were measured using quantitative RT-PCR, ELISA and immunohistochemistry staining. Results: Tendinopathic tissues demonstrated significantly increased levels of the danger molecule HMGB1 compared with control tissues with early tendinopathy tissue showing the greatest expression. The addition of recombinant human HMGB1 to tenocytes led to significant increase in expression of a number of inflammatory mediators, including interleukin 1 beta (IL-1β), IL-6, IL-33, CCL2 and CXCL12, in vitro. Further analysis demonstrated rhHMGB1 treatment resulted in increased expression of genes involved in matrix remodelling. Significant increases were observed in Col3, Tenascin-C and Decorin. Moreover, blocking HMGB1 signalling via toll-like receptor 4 (TLR4) silencing reversed these key inflammatory and matrix changes. Conclusion: HMGB1 is present in human tendinopathy and can regulate inflammatory cytokines and matrix changes. We propose HMGB1 as a mediator driving the inflammatory/matrix crosstalk and manipulation of the HMGB1/TLR4 axis may offer novel therapeutic approaches targeting inflammatory mechanisms in the management of human tendon disorders

Oral Mutian®X stopped faecal feline coronavirus shedding by naturally infected cats

Feline coronavirus (FCoV) is common among cats living indoors in groups. In about 10% of infected cats, a potentially lethal disease, feline infectious peritonitis (FIP) occurs. Virus transmission is faecal-oral. Mutian® Xraphconn (Mutian X) is a product marketed to treat cats with FIP but is also being used to stop virus shedding, although no clear guidelines exist for its use for this purpose. The aim of this study was to establish the minimum dose and treatment duration required to ensure viral clearance from the faeces of asymptomatic virus-shedding cats. In five multicat households, 29 cats naturally infected with FCoV and actively shedding virus in the faeces were given Mutian X pills. Virus shedding was monitored using reverse-transcription quantitative polymerase chain reaction (RT-qPCR) controlled for faecal inhibitors to ensure sensitivity. Mutian X given orally cleared the virus in 29 cats; although four cats required a repeated course to finally stop virus shedding. A dose of 4 mg/kg q24 h for four days was found to be the optimal treatment protocol: 2 mg/kg cleared only 80% of cats. Post-treatment using a sensitive RT-qPCR test was essential to ensure that virus clearance had been achieved, since failure to clear even one cat can result in re-infection of the others. Records of virus shedding by cats before treatment provided a retrospective control: significantly more cats stopped shedding virus after Mutian X than recovered from infection during the control period (p &lt; .00001). This is the first report of the successful elimination of faecal FCoV shedding in chronically infected cats

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

Background: Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging. Results from the ECLIPSE study, an open-label, randomized, multicenter, 2-arm, phase 2 study evaluated the safety of deferasirox dispersible tablet and film-coated tablet (FCT) formulations in patients with transfusion-dependent thalassemia (TDT) or very low, low, or intermediate risk myelodysplastic syndrome (MDS) treated over 24 weeks. Methods: The aim of the current study (a 2-year, open-label, multicenter, single-arm, phase 3 study) is to evaluate the long-term safety and efficacy of deferasirox FCT in a subset of patients with TDT or lower/intermediate-risk MDS treated for 2 years after the completion of 24 weeks of treatment with deferasirox in the ECLIPSE phase 2 study. Results: Of 53 patients enrolled, 34 (64.2%) completed treatment and study. Adverse events (AEs) reported in most patients (similar to 70%) were of mild to moderate severity. Headache and diarrhea were the most frequently (&gt; 25%) reported AEs. None of the serious AEs (including 1 death) were considered treatment related. No new safety signal was identified, and long-term safety of deferasirox FCT was consistent with the known safety profile of deferasirox. No major concerns associated with gastrointestinal tolerability, renal safety, or hematological abnormalities (thrombocytopenia/neutropenia) were reported during the 2 years. Patients receiving deferasirox FCT had a treatment compliance (by pill count) of similar to 90% and persistence (continuous use for &gt;= 30 days) of &gt; 95%. Reduction in serum ferritin level was almost consistent starting from week 2 across all post-baseline time points (relative reduction: month 6, 19%; month 12, 29%). Conclusions: The results from this 2-year interventional study suggest that the recommended dosing of deferasirox FCT, with better tolerability, palatability, and compliance, offers a favorable option of ICT for long-term management of iron overload and associated complications in TDT

Electron-impact ionization of atomic hydrogen at 2 eV above threshold

The convergent close-coupling method is applied to the calculation of fully differential cross sections for ionization of atomic hydrogen by 15.6 eV electrons. We find that even at this low energy the method is able to yield predictive results with small uncertainty. As a consequence we suspect that the experimental normalization at this energy is approximately a factor of two too high.Comment: 10 page

Submillimeter-wave sideband generation using a planar diode array

A 36 element array of planar Schottky diodes is used to mix the output of a CO_2 pumped far infrared laser with a 1-20 GHz microwave source to generate tunable sidebands at 1.6 THz. The double sideband power was measured by heterodyne detection with a 1T23 corner cube Schottky diode for a calculated output power of 5.9 μW with a 28 dB conversion loss